Immunicum AB (DE:1YG0)

FRANKFURT:1YG0

1YG0

Immunicum AB

RESEARCH TOOLSreports

Immunicum AB (1YG0) Price & Analysis

1 Followers

1YG0 Stock Chart & Stats

€0.49

-€0.01(-1.68%)

At close: Jan 08 4:00 PM EST

€0.49

-€0.01(-1.68%)

Day’s Range― - ―

52-Week Range€0.35 - €0.87

Previous CloseN/A

Volume0.00

Average Volume (3M)16.00

Market Cap

€28.85M

Enterprise Value€233.33M

Total Cash (Recent Filing)€74.13M

Total Debt (Recent Filing)€18.67M

Price to Earnings (P/E)―

Beta0.31

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.90

Shares Outstanding62,584,580

10 Day Avg. Volume50

30 Day Avg. Volume16

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)0.50

Price to Sales (P/S)0.00

P/FCF Ratio-3.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.15

Revenue Forecast (FY)€230.28K

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetPersistently low debt (D/E ~3% TTM) materially reduces near-term solvency risk and preserves strategic optionality. With limited leverage the company can prioritize R&D spending or seek partnerships without acute refinancing pressure, supporting continuation of clinical programs over months.

Specialized Immuno-oncology PlatformA focused cell-based immuno-oncology R&D platform is a durable competitive asset: technical expertise and clinical-stage programs (e.g., renal cell carcinoma) create licensing and partnership optionality. This specialization increases the chance of strategic deals that can fund development over the medium term.

Improving Cash Burn TrendA reduction in cash burn versus 2023 indicates operational progress toward lower funding needs. While FCF remains negative, a smaller burn rate lengthens runway, lowering immediate financing urgency and improving the odds management can advance trials or secure collaborations within months.

Bears Say

Revenue CollapseNear-zero revenue removes recurring cash inflows that underpin sustainable operations. Without product sales the company must rely on financings or partnerships to fund R&D and trials; this structural absence of commercial revenue heightens execution and financing risk over the 2–6 month horizon.

Persistent Negative Cash FlowContinuous negative OCF and FCF across reported periods means the business is not self-financing. This persistent cash burn forces repeated external financing or asset monetization, increasing dilution or covenant risk and potentially constraining trial timelines and R&D investment.

Large Operating LossesSustained large operating losses erode shareholder equity and produce negative returns on capital. Ongoing unprofitable operations reduce negotiating leverage for partnerships, raise the bar for milestone-driven deals, and make long-term independence difficult without successful clinical readouts or significant financing.

1YG0 FAQ

What was Immunicum AB’s price range in the past 12 months?

Immunicum AB lowest stock price was €0.35 and its highest was €0.87 in the past 12 months.

What is Immunicum AB’s market cap?

Immunicum AB’s market cap is €28.85M.

When is Immunicum AB’s upcoming earnings report date?

Immunicum AB’s upcoming earnings report date is Aug 20, 2026 which is in 67 days.

How were Immunicum AB’s earnings last quarter?

Immunicum AB released its earnings results on May 08, 2026. The company reported -€0.031 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.031.

Is Immunicum AB overvalued?

According to Wall Street analysts Immunicum AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immunicum AB pay dividends?

Immunicum AB does not currently pay dividends.

What is Immunicum AB’s EPS estimate?

Immunicum AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immunicum AB have?

Immunicum AB has 62,584,580 shares outstanding.

What happened to Immunicum AB’s price movement after its last earnings report?

Immunicum AB reported an EPS of -€0.031 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.226%.

Which hedge fund is a major shareholder of Immunicum AB?

Currently, no hedge funds are holding shares in DE:1YG0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immunicum AB

Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.